rHuman FLt3 Active
- Known as:
- rHuman FLt3 Active
- Catalog number:
- RF00394041-5
- Product Quantity:
- 5
- Category:
- -
- Supplier:
- Agren
- Gene target:
- rHuman FLt3 Active
Related genes to: rHuman FLt3 Active
- Gene:
- FLT3 NIH gene
- Name:
- fms related tyrosine kinase 3
- Previous symbol:
- -
- Synonyms:
- STK1, FLK2, CD135
- Chromosome:
- 13q12.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-07-30
- Date modifiied:
- 2019-04-23
Related products to: rHuman FLt3 Active
Related articles to: rHuman FLt3 Active
- The TAM family of receptor tyrosine kinases (TYRO3, AXL, MERTK) promotes tumor survival, metastasis, and immune evasion. Its dysregulation across solid and hematologic cancers is associated with therapy resistance and poor outcomes. FLT3 is a key oncogenic driver in acute myeloid leukemia (AML). We report the preclinical characterization of CPL423, a low-molecular-weight inhibitor of all TAMs and FLT3. - Source: PubMed
Publication date: 2026/03/25
Mikołajczyk AgataPopiel DelfinaJastrzębska KingaWiernicki BartoszMituła FilipJanusz ArturDominowski JakubGórka MichałKornatowski TomaszHucz-Kalitowska JoannaTeska-Kamińska MałgorzataSmuga DamianDelis MonikaKamecki KrystianMaliszewski PawełYamani AbdellahDubiel KrzysztofPieczykolan JerzyWieczorek Maciej - Dendritic cells play a critical role in immunity. Fms-related tyrosine kinase 3 ligand (FLT3L) is a cytokine that can promote the expansion and differentiation of bone marrow dendritic cells (DC) progenitors. RO7497987 (FLT3L-Fc) is a novel FLT3 agonist developed to extend the half-life of FLT3L and induce expansion of peripheral blood DC. - Source: PubMed
Publication date: 2026/03/24
Iacovelli Anthony JSanjabi ShomysehMonemi ShararehAmitai AssafDecalf JérémieMoussion ChristineLiao Michael ZRao Gautham KGetz JenniferMancuso Michael R - Not available. - Source: PubMed
Publication date: 2026/04/09
Bornhäuser Martin - Not available. - Source: PubMed
Publication date: 2026/04/09
Angotzi FrancescoBorlenghi ErikaSartor ChiaraGiannini Maria BenedettaMarconi GiovanniTamellini EdoardoTurrini MauroLoscocco FedericaAudisio ErnestaFederico VincenzoVetro CalogeroGrimaldi FrancescoVisentin AndreaFerrara FelicettoTrentin LivioGurrieri CarmelaLessi Federica - QuANTUM-First (NCT02668653) demonstrated improved overall survival (OS) in FLT3-ITD-positive patients with newly diagnosed acute myeloid leukemia (ndAML) treated with quizartinib plus standard chemotherapy. Herein, we evaluated the impact of post-consolidation/post-transplant single-agent maintenance therapy on clinical outcomes in patients receiving maintenance, focusing on measurable residual disease (MRD) status at maintenance onset. Overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) were prespecified exploratory analyses. Cumulative incidence of relapse (CIR), analyses by allogeneic hematopoietic stem cell transplant (allo-HCT), and analyses by MRD status were post-hoc and not powered for statistical significance. Samples for FLT3-ITD MRD analysis were collected in composite complete remission patients ≤30 days before receiving maintenance and assessed by an ultrasensitive amplicon-based assay. More transplanted quizartinib-treated patients received maintenance (71%) vs placebo (55%); OS benefit was not demonstrated among these patients. In patients who did not undergo allo-HCT, quizartinib maintenance was associated with a significant OS benefit (HR 0.401; 95% CI, 0.192-0.838), including a benefit in patients who were MRD-negative at the start of maintenance (OS HR of 0.194, 95% CI, 0.056-0.676). Patients who were MRD-negative at the completion of consolidation achieved 89.1% (95% CI, 70.0%-96.4%) survival at 3 years with quizartinib maintenance in the absence of allo-HCT. These data suggest that for patients who achieve FLT3-ITD MRD negativity after induction and consolidation with quizartinib, maintenance with quizartinib provides a significant survival benefit and in some patients may eliminate the need for allo-HCT. - Source: PubMed
Publication date: 2026/04/08
Levis Mark JErba Harry PMontesinos PauPatkowska ElzbietaCortes Jorge EPerl Alexander EDombret HervéAmadori SergioWang JianxiangSchlenk Richard FLiu LiMostafa Kamel YasserImadalou KarimaLaadem AbderrahmaneBurns KristySekeres Mikkael A